BRAF and cutaneous melanoma: The expression of various receptor tyrosine kinases, including AXL, PDGFRB, and EGFR, in cutaneous melanoma occurs in MITFlow melanoma cells with a proinvasive potential and has been associated with BRAF/MEK inhibitor resistance [3,12,18,19,41,42,43].